A Comprehensive Update on the Recent Advancements in the Treatment of Chronic Hepatitis B: Is it Feasible to Attain a Complete Cure-Practical Hurdles
DOI:
https://doi.org/10.17140/lroj-5-116Keywords:
Chronic hepatitis B, cccDNA, Direct-acting antivirals (DAA’s), Host targeted treatments (HTT), Genome editing technologiesAbstract
Background: Hepatitis B virus (HBV) discovery occurred over half a century ago; however, about 300 million patients with chronic hepatitis B (CHB) still live in the world, leading to approximately one million deaths every year. Despite the fact that presently recommended antivirals (for instance, nucleoside analogs) are efficacious at reducing HBV replication, they practically do not impact the present HBV covalently closed circular deoxyribonucleic acid (cccDNA) reservoir. HBV cccDNA is a key barrier to the total depletion of the virus via antiviral therapy. Having reviewed earlier HHBV and CHB cures, we have updated the latest advancements in this field.
Methods: A narrative review was performed with the search engines Pubmed, Google Scholar, and others, using the MeSH terms, for instance. “Plausible Therapies; antivirals”; “NAs”; “pegylated-interferon-alpha (PEG-IFNα)”; “direct-acting antivirals (DAA’s)”; “Core protein allosteric modulator (CpAM)”; “post-transcriptional regulation”; “Host targeted treatments (HTT)”; “agents hampering viral entry”; “targeting cccDNA directly; epigenetics”; “DNA methylation”; “Histone post-translational modifications”; “DNA methylation”; “Histone acetylation”; “Histone deacetylase”; “zinc finger nucleases”; (TALEN)”; “CRISPR/Cas9”; “Designer nuclease(s)” from 2000 till date in 2024 February.
Results: We found a total of 900 articles, out of which we selected 142 for this review. No meta-analysis was done.
Conclusions: The true cure for HBV infection requires the elimination of viral cccDNA from HBV-infected cells; thus, the generation of new agents directly or indirectly targeting HBV cccDNA is the immediate requirement of restricting presently available drugs against HBV infection. Regarding this, it is the major focus of current anti-HBV research worldwide via separate modes to either inactivate or inhibit (functional cure) or eliminate (complete cure) BV cccDNA. Here we provide present advances and challenges for inactivating, silencing, or depleting viral cccDNA using anti-HBV agents from various sources, like small molecules (inclusive of epigenetic drugs), polypeptides, and proteins, small interfering ribonucleic acid (siRNA), or gene-editing strategies targeting or attenuating HBV cccDNA via several modes, and future directions that might be taken into account in efforts to truly cure chronic HBV infection. Till now, no breakthrough has been made in ameliorating HBV cccDNA, despite the fact that a plethora of candidates have advanced into the phase of clinical trials. Moreover, considerable substances work to indirectly target HBV cccDNA. No special substance possesses the capacity to directly target HBV cccDNA. Specifically, CCCC_R08, in addition to nitazoxanide, might be some of the most favorable compounds to clear HBV infection in small-molecule agents. Furthermore, CRISPR-Cas9 systems have the capacity to directly target HBV cccDNA for decay and illustrate significant anti-HBV activity. Consequently, gene-editing targeting HBV cccDNA might be one of the most attractive means for achieving the core goal of anti-HBV therapeutic approaches. Basic studies on HBV infection are required to get rid of these hurdles.
References
Yuen MF, Chen DS, Dusheiko GM, et al. Hepatitis B virus infection. Nat Rev Dis Primer. 2018; 4: 18035. doi: 10.1038/ nrdp.2018.35
Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver dis-eases in the world. J Hepatol. 2019; 70: 151-171. doi: 10.1016/j. jhep.2018.09.014
Lai CL, Yuen MF. Prevention of hepatitis related hepatocel-lular carcinoma with anti viral therapy. Hepatology. 2013; 57: 399- 408. doi: 10.1002/hep.25937
Kaur KK, Allahbadia GN, Singh M. Potential role of Epigen-etic Modulation in prevention or therapy for Diabetic Kidney Disease-still a dream or a reality –A Systematic Review. J Diab Nephro Diab Mgmt. 2021: 1: 1-26.
Kaur KK, Allahbadia GN,Singh M. How does Epigenetics Regulate Development of Placenta and Placental Pathologies like PreEclampsia(PE),Intrauterine growth Restriction( IUGR)-With Main emphasis on PE’. Advances in Bioengineering and Biomedical Sci-ence Research. 2021.
Kaur KK, Allahbadia GN, Singh M. An update on genome editing with the utilization of CRISPR/Cas 9 system for evalu-ation and treatment of human diseases - a systemic review. Curr Trends Biomedical Eng & Biosci. 2022; 20(5): 556046. doi: 10.19080/ CTBEB.2022.20.556046
Kaur KK, Allahbadia GN, Singh M. The role of utilization of epigenetics treatment strategies regarding hepatitis B virus co-valently closed circular DNA silencing with the aim of attaining cure: A narrative review. 2022.
Kaur KK, Allahbadia GN, Singh M. An update on the method-ology hepatitis B virus (HBV) uses for its lifecycle: from nuclear import of capsid to cccDNA for permanent HBV cure acquisi-tion/avoidance of persistence of cccDNA. Genesis J Microbiol Im-munol. 2023; 1(1): 4.
Kaur KK, Allahbadia GN, Singh M. Targeting dysfunctional Mitochondrial Metabolism of Hepatocytes caused hepatitis B virus(HBV) in the treatment of the Chronic HBV infection - a Narrative Review. J Hum Virol Retrovirol. 2024; 11(1): 4-12. doi:
15406/jhvrv.2024.11.00273 10. Lok AS, Zoulim F, Dusheiko GM, et al. Hepatitis B cure: From discovery to regulatory approval. Hepatology. 2017; 66: 1296-1313.
Lampertico P, Agarwal K, Berg T. EASL Practice Clini-cal management Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67(2): 370-398. doi: 10.1016/j. jhep.2017.03.021
Gish R, Jia JD, Lorcanini S, et al. Selection of chronic hepati-tis B therapy with high barrier to resistance. Lancet Infect Dis. 2012; 12: 341-53. doi: 10.1016/S1473-3099(11)70314-0
Yip TC, WongVW, ChianHJ, et al. Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with Chronic HBV infection in China. Gastroenterology. 2020; 158: 215-225.e216. doi: 10.1053/j.gastro.2019.09.025
Phillips S, Chokshi S, Riva A, et al. CD8(+)T-cells control of hepatitis B virus viral replication: direct comparison between cy-tolytic and non-cytolytic functions. J Immunol. 2010; 184: 287-295. doi: 10.4049/jimmunol.0902761
Chokshi S, Cooksley H, Riva A, et al. Identification of serum cytokine profiles associated with HBeAg seroconversion follow-ing anti viral treatment interruption. Viral Immunol. 2014; 27: 235- 44. doi: 10.1089/vim.2014.0022
Cooksley H, Riva A, KatzarovK, et al. Differential expres-sion of immune inhibitory checkpoint signatures on anti viral and inflammatory T-cells population in chronic HBV patients. J Inter-feron Cytokine Res. 2018; 38: 273-282 . doi: 10.1089/jir.2017.0109
Evans A, Riva A , Cooksley H, et al. Programmed death(PD-1) expression during antiviral treatmentof chronic hepatitis B: Im-pact of Hepatitis B e antigen. Hepatology. 2008; 48: 759-769.
Boni C, Laccabue D, Lampertico P, et al. Restored function of HBV specific T-cells long term effective therapy with nucleos(t) ide analogues. Gastroenterology. 2012; 143: 963-973.e969. doi: 10.1053/j.gastro.2012.07.014
Micco L, Peppa D, Loggi E, et al. Differential boosting of in-nate and adaptive antiviral responses during pegylated interferon-alpha therapy of Chronic hepatitis B. J Hepatol. 2013; 58: 225-233. doi: 10.1016/j.jhep.2012.09.029
Penna A, Laccabue D,Libri I, et al. Peg interferon- α does not improve early peripheral blood HBV specific T-cell responses in HBeAg negative chronic hepatitis. J Hepatol. 2012; 56: 1239-1246. doi: 10.1016/j.jhep.2011.12.032 Narrative Review | Volume 5 | Number 1 | Kaur KK, et al
Carotenuto P, Artsen A, Niesters HG, et al. In vitro use of au-tologous dendritic cells improves detection of T-cell responses to hepatitis B virus(HBV) antigens. J Med Virol. 2009; 81: 332-339. doi: 10.1002/jmv.21333
Reinharz V, Ishida Y, Tsuge M , et al. Understanding hepatitis B virus dynamic and the antiviral effects interferon-alpha treat-ment in humanized chimeric mice. J Virol. 2021; 95: eoo49220. doi: 10.1128/JVI.00492-20
Cheng J, Zhao Q, Zhou Y, et al. Interferon-alpha induces mul-tiple cellular protein that coordinately suppresses hepadnaviral covalently closed circular DNA transcription. J Virol. 2020; 94: eoo442-20. doi: 10.1128/JVI.00442-20
Wang G, Guan G, Khan NU, et al. Potential capacity of interferon-α to eliminate covalently closed circular DNA (cccD-NA) in hepatocytes infected with hepatitis B virus. Gut Pathogen. 2021; 13: 1-10. doi: 10.1186/s13099-021-00421-9
Li Y, Xia Y, Han M, et al. IFN-α- mediated base excision re-pair pathway correlates with antiviral responses against hepatitis B virus infection. Sci Rep. 2017; 7: 12715. doi: 10.1038/s41598- 017-13082-z
Zoulim F, Lebosse F, Levrero M. Current treatments chronic hepatitis B virus infection. Curr Opin Virol. 2016; 18: 109-116. doi: 10.1016/j.coviro.2016.06.004
Sonneveld MJ, Janssen HL. Chronic hepatitis B: Peg interferonα or Nucleos(t)ide analogues? Liver Int. 2011; 31(Sup-pl1): 78-84. doi: 10.1111/j.1478-3231.2010.02384.x
Nishio A, Bolte FI, Takeda K, et al. Clearance of pegylated interferon by Kupffer cells (KC’s) limits NK-cell activation and therapy response in patients with HBV infection. Sci Transl Med. 2021; 13: eaba6322. doi: 10.1126/scitranslmed.aba6322
Ahn SH, Marcelin P, MaX, et al. Hepatitis B surface antigen loss with tenofovir disoproxil fumarateplus Peg interferonα–2a: Week 2 analysis. Dig Dis Sci. 2018; 63: 3487-3497. doi: 10.1007/ s10620-018-5251-9
Hagiwara S, Nishida N, Watanabe T , et al. Sustained antiviral effects and clearance of Hepatitis B surface antigen after therapy with entecavir and pegylated interferon in chronic hepatitis B. Anti Viral Ther. 2018; 23: 513-5s21. doi: 10.3851/IMP3225
Lampertico P, Brunetto MR, Craxi A, et al. Add on peg interferonα – 2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B e antigen- negative Chronic hepatitis B genotype D. J Viral Hepat. 2019; 26: 118-125. doi: 10.1111/ jvh.12999
Chong CH, Lim SG. When can we stop nucleoside analogues in patients with chronic hepatitis B? Liver Int. 2017; 37(Suppl1): 52-58. doi: 10.1111/liv.13314
Hadziyannis SJ, Sevastianos V, Rapti I, et al. Sustained re-sponses and loss of HBsAg in HBeAg negative patients with chronic hepatitis B who stop long term treatment with adefo-vir. Gastroenterology. 2012; 143: 629-36.e621. doi: 10.1053/j.gas-tro.2012.05.039
Van Bommel F, Berg T. Risks and benefits of discontinuation nucleos(t)ide analogue treatment:a treatment concept for patients with HBeAg negative chronic hepatitis B. Hepatol Commun. 2021; 5: 1632-1648. doi: 10.1002/hep4.1708
Garcia- Lopez M, Lens S, Pallett LJ, et al. Viral and immune factors associated with successful treatment withdrawl in HBeAg negative chronic hepatitis B patients. J Hepatol. 2021; 74: 1064- 1074. doi: 10.1016/j.jhep.2020.11.043
Jeng WJ,I-Shyan Sheen, Chen YC, et al. Off therapy durability of response to entecavir therapy in HBeAg negative chronic hep-atitis B patients. Hepatology. 2013; 58: 1888-1896. doi: 10.1002/ hep.26549
Phillips S, Jagatia R, Chokshi S. Novel therapeutics strategies for chronic hepatitis B. Virulence. 2022; 13(1): 1111-1132. doi: 10.1080/21505594.2022.2093444
Yang L, Liu F, Tong X, et al. Treatment of chronic hepatitis B virus infection using small molecule modulators of nucleocapsids assembly: Recent advances and perspectives. ACS Infect Dis. 2019; 5: 713-724. doi: 10.1021/acsinfecdis.8b00337
Nijapatnam DC, LiottaDC. Recent advances in the devel-opment HBVcapsid assembly modulators. Curr Opin Chem Biol. 2019; 50: 73-79 doi: 10.1016/j.cbpa.2019.02.009
Yuen MF, Zhou Y, Gane E,et al. Safety, pharmacokinetics an-tiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: A multicenter, randomized, placebo-controlled phase 1trial. Lancet Gastroenterol Hepatol. 2021; 6: 723-732. doi: 10.1016/S2468-1253(21)00176-X
Zhang H, Wang F, Zhu X, et al. Antiviral activity and pharma-cokinetics of the hepatitis B virus (HBV) capsid assembly modu-lator GLS4 of patients with Chronic HBV infection. Clin Infect Dis. 2020; 73: 175-182. doi: 10.1093/cid/ciaa961
Zhao N, Jia B, Zhao H, et al. A first in human trial of GLS4, a novel inhibitor of hepatitis B virus capsid assembly following single and multiple ascending dose studies withor without ritona-vir in healthy adult volunteers. Antimicrob Agents Chemother. 2019; 64: e01686-19. doi: 10.1128/AAC.01686-19
Rat V, Signeuret F, Burlaud-Gaillard J, et al. BAY41-4109 me-diated aggregation of assembled and misassembled HBVcapsids in cells revealed by electron microscopy. Antiviral Res. 2019; 169: 104557. doi: 10.1016/j.antiviral.2019.104557
Berke JM, Dehertogh P, Vergauwen K, et al. Antiviral prop-erties and mechanism of action studies of the hepatitis B virus capsid assembly modulator JNJ-56136379. Antimicrob Agents Che-mother. 2020; 64: e02439-02419. doi: 10.1128/AAC.02439-19
Klumpp K, Shimada T, Allweiss L, et al. Efficacy of NVR-3-778 alone and in combination with pegylated interferonvs en-tecavir in uPA/SCID mice with humanized liver and HBV in-fection. Gastroenterology. 2018; 154: 652-62.e658. doi: 10.1053/j. gastro.2017.10.017
Yuen MF, Gane E, Kim DJ, et al. Antiviral activity, safety and pharmacokinetics of capsid assembly modulator NVR-3-778 in patients with chronic hepatitis B virus infection. Gastroenterology. 2019; 156:c1392-1403.e1397. doi: 10.1053/j.gastro.2018.12.023
Zoulim F, Lenz O, Vandenbossche JJ, et al. JNJ-56136379, an HBV capsid assembly modulator, is well tolerated and has Antiviral activity in a phase 1 study of patients with chronic in-fection. Gastroenterology. 2020; 159: 521-33.e529. doi: 10.1053/j. gastro.2020.04.036
Edward Gane MS, Ma X, Nguyen T, et al. Viral response and safety following discontinuation of treatment with the core inhib-itor-vebicorvir and a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg positiveor negative chronic hepatitis B virus infection. J Hepatol. 2021; 75: S736.
Yuen MF, Agarwal K, Gane EJ, et al. Safety, pharmacokinet-ics and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: A randomized, placebo- controlled phase 1trial. Lan-cet Gastroenterol Hepatol. 2020; 5: 152-166. doi: 10.1016/S2468- 1253(19)30346-2
Meng Z, Lu M. RNA interference induced innate immunity, off target effect or immune adjuvant? Front Immunol. 2017; 8: 331. doi: 10.3389/fimmu.2017.00331
Woodell CI, Yuen MF, Cha HL, et al. RNAi treatment chroni-cally infected patients and chimpanzees reveals integrated hepa-titis B virus DNA is a source of HBsAg. Sci Transl Med. 2017; 9: eaan0241. doi: 10.1126/scitranslmed.aan0241
Gane EJ, Locarnini S, Lim TH, et al. Short term treatment with RNA interference therapy, JNJ-3989 combination therapy results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide ana-logue treatment. J Hepatol. 2020; 73: S20. doi: 10.1016/S0168- 8278(20)30597-3
Yuen MF, Berliba E, Sukeepaisarnjaornen W, et al. Repeat dosing of GalNac-si RNA AB 729 in subjects with chronic hepa-titis B results in robust and sustained HBsAg suppression. J Hepa-tol. 2021; 75: S203.
Thi EP, Yuen MF, Gane E, et al. Inhibition of hepatitis B sur-face antigen by RNA interference therapeutic AB 729 in chronic hepatitis B patients correlates with suppression of all HBsAg iso-forms and HBV RNA. J Hepatol. 2021; 75: S760.
Bhavna Paratala JJ, Ganchua SC, Gane E, et al. Inhibition of hepatitis B surface antigen therapeutic AB 729 in chronic hepati-tis B subjects by RNA interference is accompanied by upregula-tion of HBV specific T-cells activation markers. J Hepatol. 2021; 75: S761.
Gane E, Yuen MF, Anderson M, etal. A single dose of Gal-Nac-si RNA AB 729, results in prolonged reductions in HBsAg, HBcrAg, HBV DNA and HBV RNA in the absence of nucleos(t) ide analogue therapy. J Hepatol. 2021; 75: S762.
Yuen M-F, Lim Y-S, Cloutier D, Shen L, et al. Preliminary on treatment data from a phase 2 study evaluating VIR-218 in com-bination with pegylated interferon-2α in participants with chronic hepatitis B infection. J Hepatol. 2021; 75: S738.
Kaufmann SHE, Dorhoi A, Hotchkiss RS, et al. Host directed therapies for bacterial and viral infections. Nat RevDrug Discov. 2018; 17: 35-56. doi: 10.1038/nrd.2017.162
Allweiss L,Volz T, Giersch K, et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus, reinfec-tion efficiently deplete nuclear cccDNA in vivo. Gut. 2018; 67: 542-552. doi: 10.1136/gutjnl-2016-312162
Bogomolov P, Alexander A, Vorankova N, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results phase 1b/IIb study. J Hepatol. 2016; 65: 490-498. doi: 10.1016/j.jhep.2016.04.016
Watashi K, Sluder A, Daito T, et al. Cyclosporin a and its ana-logues inhibit hepatitis B virus entry into hepatocytes targeting a membrane transporter, Sodium-taurocholate-co transporting peptide(NTCP). Hepatology. 2014; 59: 1726-1737. doi: 10.1002/ hep.26982
Liu Y, Ruan H, Li Y, et al. Potent and specific inhibition of NTCP mediated HBV/HDV infection and substrate transport-ing by a novel, oral available CyclosporinA analogue. J Med Chem. 2021; 64: 543-565. doi: 10.1021/acs.jmedchem.0c01484
Sneha V, Gupta AA, Fanger MC, et al. Preliminary pharma-cokinetics and safety in healthy volunteersof VIR 3434, a mono-clonal antibody the treatment of chronic hepatitis B infection. J Hepatol. 2021; 75: S733.
Bazinet M, Pantea V, Cebotarescu V, et al. Safety and effi-cacy of REP 2139 and pegylated interferon-2α hepatitis B virus and hepatitis D virus co infection infection(REP301 and RE-P301LTF: A non randomized, phase 2 trial. Lancet Gastroenterol Hepatol. 2017; 2: 877-889. doi: 10.1016/S2468-1253(17)30288-1
Bazinet M, Pantea V, Placinta G, et al. Safety and efficacy of48 weeks REP 2139 or REP 2165, tenofovir disoproxil and pe-gylated interferon-2α in patients with chronic infection naïve to nucleos(t)ide therapy. Gastroenterology. 2020; 158: 2180-2194. doi: 10.1053/j.gastro.2020.02.058 Narrative Review | Volume 5 | Number 1 | Kaur KK, et al
Lecor-Hersckovich LS, Bazinet M, Pantea V, et al. HBsAg, anti HBs, and ALT kinetic characterization during NAP based combination therapy of HBeAg negative chronic hepatitis B vi-rus infection. J Hepatol. 2021; 75: S750.
Blanchet M, Sinnathamby V, Vaillant A, et al. Inhibition of HBeAg secretion by nucleic acid based polymers effective in-HepG2.2.15 cells. Antiviral Res. 2019; 164: 97-105. doi: 10.1016/j. antiviral.2019.02.009
Real C, Werner M, Paul A, et al. Nucleic acid based polymers effective against hepatitis B virus infection in patients don’t har-borimmunostimulatory properties in primary isolated liver cells. Sci Rep. 2017; 7: 43838. doi: 10.1038/srep43838
Mouzanaar K, Fusil F, Lacombe B, et al. Farsenoid X nuclear receptor-α is a pro viral host factorfor hepatitis B virus that is inhibited by ligands in vitro and in vivo. FASEB J. 2019; 33: 2472- 2483. doi: 10.1096/fj.201801181R
Scalfaro P, Heo J, Liu CJ, et al. A phase 2 study testing FXR agonist vonafexor in treatment-naïve patients with chronic hep-atitis B(CHB): Preliminary week 16 results. J Hepatol. 2021; 75: S761.
Wang P, Heitman J. The cyclophilins. Genome Biol. 2005; 6: 226. doi: 10.1186/gb-2005-6-7-226
Galat A. Peptidylprolyl cis/trans isomerases (immunophilins: Biological diversity-targets-functions. Curr Top Med Chem. 2003; 3: 1315-1347. doi: 10.2174/1568026033451862
Selyutina A, Persaud M, Simons LM, et al. Cyclophilin a pre-vents HIV1 restriction in lymphocytes by blocking of TRIM5α binding to the viral core. Cell Rep. 2020; 30: 3766-777.e3766. doi: 10.1016/j.celrep.2020.02.100
Cheng S, Luo M, Ding C, et al. Downregulation of Peptidyl-prolyl isomerase a promotes cell death andenhances doxorubi-cin induced apoptosis in Hepatocellular carcinoma (HCC ). Gene. 2016; 591: 236-244. doi: 10.1016/j.gene.2016.07.020
Stanciu C, Trifan A, Muzica C, et al. Efficacy and safety of alisporivir for the treatmentof hepatitis C infection. Exp Opin Phar-macother. 2019; 20: 379-384. doi: 10.1080/14656566.2018.1560424
Phillips S, Chokshi S, Chatterji U, et al. Alisporivir inhibition of hepatocyte cyclophilins reduced HBV replication and hepatitis B surface antigen production. Gastroenterology. 2015; 148: 403-414. e7. doi: 10.1053/j.gastro.2014.10.004
Nilsson J, Mpss S, Coates N, et al. P1044NVP018, a cy-clophilin inhibitor for the treatmentof chronic HBV infection. J Hepatol. 2014; 60: S423.
Gallay P, Ure D, Bobardt M, et al. The cyclophilin inhibitor CRV431 inhibits HBV DNA and HBsAg in transgenic mice. PLoS One. 2019: 14: e0217433. doi: 10.1371/journal.pone.0217433
Kuo J, Bobardt M, Chatterji U, et al. A pan-cyclophilin inhibi-tor CRV431 decreases fibrosis and tumor development in chronic liver disease models. J Pharmacol Exp Ther. 2019; 371: 231-241. doi: 10.1124/jpet.119.261099
Allweiss L, Dandri M. The role of cccDNA in HBV mainte-nance. Viruses. 2017; 9(6): 156. doi: 10.3390/v9060156
Slagle BL, Bouchard MJ. Role of HBx in Hepatitis B virus persistence and its therapeutic implications. Curr Opin Virol. 2018; 30: 32-38. doi: 10.1016/j.coviro.2018.01.007
Decorsiere A, Mueller H, vanBreuge lPC, et al. Hepatitis B virus X protein identifies the Smc 5/6 complex as a host restric-tion factor. Nature. 2016; 531: 386-389. doi: 10.1038/nature17170
Sekiba K,Otsuka M,Ohno M, et al. Inhibition of HBV tran-scription from cccDNA withNitazoxamide by targeting the HBx-DDB1interaction. Cell Mol Gastroenterol Hepatol. 2019; 7: 297-312. doi: 10.1016/j.jcmgh.2018.10.010
Rossignol JF, Brechot C. A pilot clinical trialof Nitazoxamide in the treatment of chronic hepatitis B. Hepatol Commun. 2019; 3: 744-747. doi: 10.1002/hep4.1339
Belloni L, Pollicino T, De Nicuola F, et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regula-tion of cccDNA function. Proc NatlAcad Sci USA. 2009; 106: 19975-19979. doi: 10.1073/pnas.0908365106
Guo Y-H, Li Y-N, Zhao J-R, Zhang J, Yan H. HBcbinds to CpG islands of HBV cccDNA and promotes an epigenetic permissive state. Epigenetics. 2011; 6: 720-726. doi: 10.4161/ epi.6.6.15815
Chong C, Cheng CYS, Tsoi SYJ, et al. Role of hepatitis B core protein in HBV transcription and recruitment of Histone acetyl transferasesto cccDNA minichromosome. Anti Virus Res. 2017; 144: 1-7. doi: 10.1016/j.antiviral.2017.05.003
Hu C, Liu X, Zeng Y, et al. DNA methyltransferase inhibitors combination therapy for the treatment of solid tumors: Mecha-nism and clinical implications. Clin Epigenet. 2021; 13: 166. doi: 10.1186/s13148-021-01154-x
Yu H, Jiang H, Cheng ST, et al. AGK2, a SIRT2inhibitor, inhibits hepatitis B virus replication in vitro and in vivo. Int J Med Sci. 2018; 15: 1356-1364. doi: 10.7150/ijms.26125
Gilmore S, Tam D, Dick R, et al. SAT-160- Anti Viral GS-5801 ,a liver targeted prodrug of a Lysine demethylase5 inhibi-tor, in a Hepatitis B virus primary human hepatocyte Infection model. J Hepatol. 2017; 66: S690-S691.
Olson M, Harris RS, H DA. APOBEC1 enzymes as targets for virus and cancer therapy. Cell Chem Biol. 2018; 25: 36-49.
Bockmann JH, Stadler D, Xia Y, et al. Comparative-analysis of the antiviral effects mediated by type1 and III interferon in hepa-titis B virus infected hepatocytes. J Infect Dis. 2019; 220: 567-577. doi: 10.1093/infdis/jiz143
Xia Y, Stadler D, Lucifora J, et al. Interferon γ and Tumor necrosis factor alphaproduced by T-cells reduce the HBV persis-tence form, cccDNA without cytolysis. Gastroenterology. 2016; 150: 194-205. doi: 10.1053/j.gastro.2015.09.026
Kostyushev D, Brezgin S, Kostyusheva A, et al. Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR/Cas9. Sci Rep. 2019; 9: 1847. doi: 10.1038/s41598-019-38526-6
Kostyushev D, Brezgin S, Kostyusheva A, Zanfyan D, Goptar I, Chulanov V. Orthologous CRISPR/Cas9 system for the deg-radation of covalently closed circular DNA of Hepatitis B virus. Cell Mol Life Sci. 2019; 76: 1779-1794. doi: 10.1007/s00018-019- 03021-8
Ates I, Rathborne T, Stuart C, et al. Delivery approaches for therapeutic Genome editing and challenges. Genes(Basel). 2020; 11: 1113. doi: 10.3390/genes11101113
Scott T, Bloom K, Moyo B, et al. Advances with using CRIS-PR/Cas9 mediated gene editing totreat infections with hepati-tis B and hepatitis C virus. Virus Res. 2018; 244: 311-320. doi: 10.1016/j.virusres.2017.01.003
Yang YC, Chen YH, Kao JH, Ching C, Liu IJ, Wang CC, et al. Permanent inactivation of HBV genomesby CRISPR/Cas9 me-diated noncleavage base editing. Mol Ther Nucleic Acids Res. 2020; 20: 480-490. doi: 10.1016/j.omtn.2020.03.005
Lang J, Neumann-Haefelin C, Thimme T. Immunological cure of HBV infection. Hepatol Int. 2019; 13: 113-124. doi: 10.1007/ s12072-018-9912-8
Neumann AU, Phillips S, Levine I, et al. Novel mechanism of antibodies to hepatitis B virus in blocking viral particles release from cells. Hepatology. 2010; 52: 875-885. doi: 10.1002/hep.23778
Chan YK, Gack MU. Viral evasion of intracellular DNA and RNA sensing. Nature Rev Microbiol. 2016; 14: 360-373. doi: 10.1038/nrmicro.2016.45
Mozer-Lisewka I, Sikora J, Kowala-Piaskowa A, Kaczmarek M, Dworacki G, Zeromski J. The incidence and significanceof pattern recognition receptors(PRR) in chronic viral hepatitis type B and C inman. Arch Immunol Ther Exp(Warz). 2010; 58: 295-302. doi: 10.1007/s00005-010-0087-9
Suslov A, Wieland S, Menne S. Modulators of innate im-munity as novel therapeutics for treatment of chronic hepatitis B. Curr Opin Virol. 2018; 30: 9-17. doi: 10.1016/j.coviro.2018.01.008
Budimir N, deHaan A, Meijerhof T, et al. Critical role of TLR7 signaling in the priming of crossprotective cytotoxic T lymphocyte responses by a whole inactivated influenza a vi-rus vaccine. PLoS One. 2013; 8: e63163. doi: 10.1371/journal. pone.0063163
Luk A, Jiang Q, Glavini K, et al. A single and multiple as-cending dose study toll like receptor7agonist ( RO7020531) in Chinese healthy volunteers. Clin Transl Sci. 2020; 30: 985-993. doi: 10.1111/cts.12791
Menne S, Tumas DB, Liu KH, et al. Sustained efficacy and seroconversion with the toll like receptor7agonist GS-9620 in the wood chuck model of chronic hepatitis B. J Hepatol. 2015; 62: 1237-1245. doi: 10.1016/j.jhep.2014.12.026
Agarwal K, Ahn SH, Elkhashab M, et al. Safety, and efficacy of Versatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment. J Viral Hepat. 2018; 25: 1331-1340. doi: 10.1111/jvh.12942
Janssen HLA, Brunetto MR, Kim YJ, et al. Safety, efficacy and pharmacodynamics of Versatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. J Hepatol. 2018; 68: 431-440. doi: 10.1016/j.jhep.2017.10.027
Herschke F, Li C, Creus AD, et al. PS-076- antiviral activity of JNJ-4964 (AL-034/TQ-A3334), a selective toll like receptor 7 agonist, in AAV/HBVmice after oral administration for 12 weeks. J Hepatol. 2019; 70: e49-e50. doi: 10.1016/S0618-8278(19)30088-X
Gane EJ, Pestaglia M, Creus AD, et al. FRI-198-a phase double blind, randomized, placebo- controlled, first in human study of the safety, tolerability, pharmacokinetics, and pharma-codynamics of oral JNJ-64794964, a toll like receptor 7 agonist, in healthy adults. J Hepatol. 2019; 70: e478. doi: 10.1016/S0618- 8278(19)30943-0
Harry A, Janssen YS, Kim HJ, et al. Safety, and efficacy of oral TLR8 agonist, Selgatolimod, in viraemic adult patients with chronic hepatitis B. J Hepatol. 2021; 75: S757.
Amin OE, Colbeck EJ, Daffis S, et al. Therapeutic potential of oral TLR8 agonist, GS-9688 (Selgatolimod)in chronic hepati-tis B: Remodeling of antiviral andregulatory mediators. Hepatol-ogy. 2021; 74: 55-71. doi: 10.1002/hep.31695
Sato S, Li K, Kumeyama T, et al. The RNA sensor RIG-1 dually functions as an innate sensor and direct antiviralfactor for hepatitis B virus. Immunity. 2015; 42: 123-132. doi: 10.1016/j.im-muni.2014.12.016
Phillips S, Mistry S, Riva A, et al. Peg-interferon lambda treatment induces robust innate and adaptive immunity in chron-ic hepatitis B patients. Front Immunol. 2017; 8: 621. doi: 10.3389/ Narrative Review | Volume 5 | Number 1 | Kaur KK, et al fimmu.2017.00621
Chan HLY, A SH, Cheng TT, et al. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A random-ized phase 2b study (LIRA-B). J Hepatol. 2016; 64: 1011-1019. doi: 10.1016/j.jhep.2015.12.018
Young Suk LimAJH, Jang JW, T WY, et al. Safety, efficacy and pharmacodynamics (PD) activity of 12 weeks treatment with oral RIG-I agonist inarigivir (IRIG), plus 48 weeks of tenofovir alafenamide in adult patients with chronic hepatitis B: A phase2 collaboration study. J Hepatol. 2021; 75: S294-S803.
Vincent IE, Zannetti C, Lucifora J, et al. Hepatitis B virus impairs TLR 9 expression and function in plasmacytoid den-dritic cells. PLoS One. 2011; 6: e26315. doi: 10.1371/journal. pone.0026315
Deng F, Ge J, Liu C, et al. Impaired expression and func-tion of TLR8 in chronic HBV infection and its association with treatment response during Peg IFNα-2a antiviral therapy. Clin Res Hepatol Gastroenterol. 2017; 41: 386-398. doi: 10.1016/j. clinre.2016.12.006
Riva A, Chokshi S. Immune checkpoint receptors: Homeo-static regulators of immunity. Hepatol Int. 2018; 12: 223-236. doi: 10.1007/s12072-018-9867-9
Gane E,Verdon D, Brooks AE, et al. Anti PD1 blockade with nivolumab with and without therapeutic vaccination for vi-rally suppressed chronic hepatitis B:a pilot study. J Hepatol. 2019; 71: 900-907. doi: 10.1016/j.jhep.2019.06.028
Lyon AR, Yousaf N, Battisti NML, et al. Immune check-point inhibitors and cardiovascular toxicity. Lancet Oncol. 2018; 19: e447-e458. doi: 10.1016/S1470-2045(18)30457-1
Ye L, Schnepf D, Staeheli P. Interferon γ orchestrates innate and adaptive mucosal immune response. Nat Rev Immunol. 2019; 19: 614-625. doi: 10.1038/s41577-019-0182-z
Koh C, Hercun J, Rahman F, et al. LBP-13-a phase 2 study of Peginterferon - lambda, lonafarnib and ritonavir for 24 weeks: End of treatment results from the LIFT HDV study. J Hepatol. 2020; 73: S130.
Chuai X, Xie B, Chen H, et al. The immune response of rhe-sus macaques to novel vaccines comprising hepatitis B virusS pre S1 and core antigens. Vaccine. 2018; 36: 3740-3746. doi: 10.1016/j. vaccine.2018.05.061
Boni C, Janssen HLA, Rossi M, et al. Combined GS4774 and tenofovirtherapy can improve HBV specific T-cell responses in patients with chronic hepatitis B. Gastroenterology. 2019; 157: 227- 241. e7. doi: 10.1053/j.gastro.2019.03.044
Al Mahtab M, Akbar SMF, Aguilar JC, et al. Treatment of chronic hepatitis B naive patients with atherapeuticvaccine con-taining HBs and HBc antigens (a randomized open and treatment controlled III Clinical trial). PLoS One. 2018; 13: e0201236.
Ma H, Lim TH, Leerapun A, et al. Therapeutic vaccine BR II-179 restores HBV specific immune responses in patients with chronic HBV in aphase 1b/IIa study. J HEP Rep. 2021; 3: 100361. doi: 10.1016/j.jhepr.2021.100361
Mehmood F, Xu R, Nisa Awan MU, et al. HBV Vaccines: Advances and development. Vaccines(Basel). 2023; 11(12): 1862. doi: 10.3390/vaccines11121862
Yuen M-F, Locarnini S, Given B, et al. First clinical experi-ence with RNA interference-based triple combination therapy in chronic hepatitis B: JNJ-3989, JNJ-6379 and a nucleos(t)ide ana-logue. Hepatology. 2019; 2019: 1489.
Ogunnaike M, Das S, Raut SS, et al. Chronic hepatitis B infection: New approaches towards cure. Biomolecules. 2023; 13(8): 1208. doi: 10.3390/biom13081208
Zeisel MB, Lucifora J, Mason WS, et al. Towards an HBV cure: State-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure. Gut. 2015; 64: 1314-1326. doi: 10.1136/gutjnl-2014-308943
Durantel D, Zoulim F. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J Hepatol. 2016; 64: S117-S131. doi: 10.1016/j.jhep.2016.02.016
Jansen L, Vaillant A, Stelma F, et al. O114: Serum HBV-RNA levels decline significantly in chronic hepatitis B patients dosed with the nucleic-acid polymer REP2139-CA. J Hepatol. 2015; 62: S250. doi: 10.1016/S0168-8278(15)30133-1 Submit your article to this journal | https://openventio.org/online-manuscript-submission-system/
Sepp-Lorenzino L, Sprague A, Mayo T. Parallel 4: Hepatitis B: Novel treatments and treatment targets: 36—GalNAc-siRNA-conjugate ALN-HBV targets a highly conserved, pan-genotypic X-orf viral site and mediates profound and durable HBsAg si-lencing in vitro and in vivo. Hepatology. 2015; 62: 222A–225A.
Dusheiko G. Will we need novel combinations to cure HBV infection? Liver Int. 2020; 40: 35-42. doi: 10.1111/liv.14371
Soriano V, Barreiro P, Cachay E, et al. Advances in hepatitis B therapeutics. Ther Adv Infect Dis. 2020; 7: 2049936120965027. doi: 10.1177/2049936120965027
Yang PL, Althage A, Chung J, Chisari FV. Hydrodynamic injection of viral DNA: A mouse model of acute hepatitis B virus infection. Proc. Natl. Acad. Sci. USA. 2002; 99: 13825-13830. doi: 10.1073/pnas.202398599
Chen J, Zhang W, Lin J, et al. An efficient antiviral strat-egyfor targeting hepatitis B virus genome using transcription activator-like effector nucleases. Mol. Ther. 2014; 22: 303-311. doi: 10.1038/mt.2013.212
Das S, Wang W, Ganesan M, et al. An ultralong-acting tenofo-vir ProTide nanoformulation achieves monthslong HBV suppres-sion. Sci Adv. 2022; 8(51): eade9582. doi: 10.1126/sciadv.ade9582
Wang W, Smith N, Makarov E, et al. A long-acting 3TC ProTide nanoformulation suppresses HBV replication in hu-manized mice. Nanomedicine. 2020; 28: 102185. doi: 10.1016/j. nano.2020.102185
Bao ZH, Dai ZK, Tang HX. Antiviral Standards for hepatitis B: An urgent need for expansion. World J Gastroenterol 2024; 30(4): 418-420. doi: 10.3748/wjg.v30.i4.418
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Liver Research (LROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.